

**Document Type** | Form

Index Number | Registry 100

**Version Number** | 1.0

Title | MPN

**Author** Annelot van Amerongen

Authorised By | Annelot van Amerongen

**Authorised On** | 22-Aug-2023

Release Date: 22-Aug-2023



☐ Unknown

EBMT Centre Identification Code (CIC):	Treatment Type	□ нст □ ст	☐ IST	☐ Other
Hospital Unique Patient Number (UPN):				
Patient Number in EBMT database:	Treatment Date _	//(YY	YY/MM/DE	))

## **MYELOPROLIFERATIVE NEOPLASMS (MPN)**

DISEASE
Note: complete this form only if this diagnosis was the indication for the HCT/CT or if it was specifically requested.  Consult the manual for further information.
Date of diagnosis: / (YYYY/MM/DD)
Classification (WHO 2016):
Primary myelofibrosis
☐ Polycythaemia vera (PV)
Essential or primary thrombocythaemia (ET)
☐ Hyper eosinophilic syndrome (HES)
Chronic eosinophilic leukaemia (CEL)
Chronic neutrophilic leukaemia (CNL)
Systemic mastocytosis
Mast cell leukaemia
☐ Mast cell sarcoma
☐ MPN not otherwise specified
Myeloid and lymphoid neoplasms with FGFR1 abnormalities (Stem cell leukaemia-lymphoma syndrome, 8p11 syndrome)
Myeloid and lymphoid neoplasms with PDGFRA rearrangement
Myeloid and lymphoid neoplasms with PDGFRB rearrangement
Myeloid and lymphoid neoplasms with PCM1-JAK2 rearrangement
Other; specify:
Therapy-related MPN: (Secondary origin)  No

Index: Registry 100 | Title: MPN | Version: 1.0 | Effective Date: 2023-08-22 | THIS IS AN UNCONTOLLED COPY



EBMT Centre Identification Code (CIC):	Treatment Type	□ нст □ ст	☐ IST	☐ Other
Hospital Unique Patient Number (UPN):				
Patient Number in EBMT database:	Treatment Date _	//(YY	YY/MM/DE	D)

Sploop size:	cm (below costal margin)	☐ Not evaluated ☐	Unknown
-	sound or CT scan:		☐ Not evaluated ☐ Unknown
Transfusion depende  No Yes Unknown		_ CIII (IIIaxiiiiuiii ulailletei)	- Not evaluated - Official
Bone marrow fibrosis  Grade 0 Grade 1 Grade 2 Grade 3 Not evaluated Unknown			
Blast count (peripher	al blood): %	t evaluated 🔲 Unknown	
Myelofibrosis only: IPSS risk score:			
☐ Low risk ☐ Intermediate-1 ☐ Intermediate-2 ☐ High risk ☐ Not evaluated ☐ Unknown  DIPSS score:			
☐ Low risk ☐ Intermediate-1 ☐ Intermediate-2 ☐ High risk ☐ Not evaluated ☐ Unknown			
MIPSS70 score:  Low risk Intermediate High risk Not evaluated Unknown			

Index: Registry 100 | Title: MPN | Version: 1.0 | Effective Date: 2023-08-22 | THIS IS AN UNCONTOLLED COPY



EBMT Centre Identification Code (CIC): Hospital Unique Patient Number (UPN):	Treatment Type	□ нст □ ст	☐ IST	☐ Other
Patient Number in EBMT database:	Treatment Date	//YY	YY/MM/DE	0)

CHRON	<b>MOSOME</b>	ANALYSIS

Chromosome analysis done before treatment (all methods including FISH): (Describe results of the most recent complete analysis)					
☐ Not done or failed					
Yes, abnormal results: number of abnormalities present:					
Yes, normal results					
☐ Unknown					
Date of chromosome analysis (if tested):I(YYYY//	MM/DD)				
Indicate below whether the abnormalities were absent, present or not	evaluated.				
abn 1 type; specify:	Absent	Present	☐ Not evaluated		
abn 5 type; specify:	☐ Absent	☐ Present	☐ Not evaluated		
abn 7 type; specify:	☐ Absent	☐ Present	☐ Not evaluated		
Trisomy 8	☐ Absent	☐ Present	☐ Not evaluated		
Trisomy 9	Absent	Present	☐ Not evaluated		
del(20q)	☐ Absent	Present	☐ Not evaluated		
del(13q)	Absent	Present	☐ Not evaluated		
Other; specify:	☐ Absent	Present			
OR					
Transcribe the complete karyotype:					

Index: Registry 100 | Title: MPN | Version: 1.0 | Effective Date: 2023-08-22 | THIS IS AN UNCONTOLLED COPY



EBMT Centre Identification Code (CIC):	Treatment Type	□ нст □ ст	☐ IST	☐ Other
Hospital Unique Patient Number (UPN):				
Patient Number in EBMT database:	Treatment Date _	//(YY	YY/MM/DE	D)

## **MOLECULAR MARKER ANALYSIS**

Molecular marker analysis done before treatment:	
□ No	
Yes	
Unknown	
Date of molecular marker analysis (if tested)://(\)	YYYY/MM/DD)
Indicate below whether the markers were absent, present or not	evaluated.
ASXL1	☐ Absent ☐ Present ☐ Not evaluated
BCR-ABL; Molecular product of t(9;22)(q34;q11.2)	☐ Absent ☐ Present ☐ Not evaluated
	☐ Absent ☐ Present ☐ Not evaluated
	If present: ☐ Type 1
Calreticulin (CALR) mutation	☐ Type 2
Caretioann (CALIT) matation	☐ Type 1 like
	☐ Type 2 like
	☐ Present but type unknown
CBL	☐ Absent ☐ Present ☐ Not evaluated
cMPL mutation	Absent Present Not evaluated
CSF3R	Absent Present Not evaluated
DDX41	Absent Present Not evaluated
ETV6	Absent Present Not evaluated
EZH2	Absent Present Not evaluated
IDH1	☐ Absent ☐ Present ☐ Not evaluated
IDH2	Absent Present Not evaluated
JAK2 mutation	Absent Present Not evaluated
KRAS	Absent Present Not evaluated
NRAS	☐ Absent ☐ Present ☐ Not evaluated
PTEN	Absent Present Not evaluated
PTPN-11	☐ Absent ☐ Present ☐ Not evaluated
RUNX1	Absent Present Not evaluated
SF3B1	☐ Absent ☐ Present ☐ Not evaluated
SRSF2	Absent Present Not evaluated
TET2	☐ Absent ☐ Present ☐ Not evaluated
TP53	Absent Present Not evaluated
U2AF1	☐ Absent ☐ Present ☐ Not evaluated
UBA1	Absent Present Not evaluated
Other; specify:	Absent Present
<u> </u>	

Index: Registry 100 | Title: MPN | Version: 1.0 | Effective Date: 2023-08-22 | THIS IS AN UNCONTOLLED COPY